Research priorities in epilepsy for the Asia-Oceanian region

Grants

Funding Acknowledgements

This report was written by experts selected by the International League Against Epilepsy (ILAE) and was approved for publication by the ILAE. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE. P. Kwan has received honoraria for speaking from Eisai, GlaxoSmithKline, and UCB Pharma, and has served on scientific advisory boards for Eisai and GlaxoSmithKline; his institution has received research funding from Eisai, GlaxoSmithKline, and UCB Pharma. W. D'Souza has received travel, investigator-initiated, speaker honoraria and has served on scientific advisory boards from UCB Pharma; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and Sanofi-Synthelabo; educational, travel, and fellowship grants from GlaxoSmithKline Neurology Australia, has served on scientific advisory boards and received honoraria from SciGen Pharmaceuticals. His institute has received research funding from GlaxoSmithKline, SciGen, Pfizer, Novartis, and UCB Pharma. All the other authors have no conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.